You have accessJournal of UrologyInfertility: Therapy1 Apr 20112279 OUTCOME OF TESTICULAR SPERM EXTRACTION COMBINED WITH INTRACYTOPLASMIC SPERM INJECTION IN AZOOSPERMIC CANCER SURVIVORS Hiroshi Okada, Yoshitomo Kobori, Hiroaki Aoki, Ryo Sato, Yoshio Ashizawa, Hiroshi Yagi, Gaku Arai, and Shigehiro Soh Hiroshi OkadaHiroshi Okada Koshigaya, Japan More articles by this author , Yoshitomo KoboriYoshitomo Kobori Koshigaya, Japan More articles by this author , Hiroaki AokiHiroaki Aoki Koshigaya, Japan More articles by this author , Ryo SatoRyo Sato Koshigaya, Japan More articles by this author , Yoshio AshizawaYoshio Ashizawa Koshigaya, Japan More articles by this author , Hiroshi YagiHiroshi Yagi Koshigaya, Japan More articles by this author , Gaku AraiGaku Arai Koshigaya, Japan More articles by this author , and Shigehiro SohShigehiro Soh Koshigaya, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2523AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Persistent azoospermic patients after anti-cancer chemotherapy have been considered sterile. We previously reported our experience with testicular sperm extraction (TESE) combined with intracytoplasmic sperm injection (ICSI) applied to postchemotherapy azoospermic men in 2006. We prospectively investigated the fertilizing ability and effects on the offspring of using testicular sperm obtained from these cancer survivors. METHODS Between 2001 and 2009 sixty-two patients who previously received chemotherapy for a variety of malignant disease underwent microdissection TESE by a single surgeon. The hormonal profile of the first visit to the male infertility clinic, histology of testicular biopsies, and outcomes of TESE-ICSI in this subgroup of patients were analyzed. We also investigated the abnormalities of offspring. Minimum follow-up period after birth was one year. RESULTS Twenty-one patients had received chemotherapy for testicular canner, seven patients for non Hodgkin lymphoma, nine patients for Hodgkin lymphoma, nine patients for acute lymphoblastic leukemia, six patients for acute myeloblastic leukemia, seven patients for rhabdomyosarcoma, and three patients for bladder cancer. Seven patients received additional radiation therapy and bone marrow transplantation. The median interval from chemotherapy to TESE was 7.2 years. Testicular sperm was obtained in 30 patients. Chemical pregnancy was achieved in 22 patients, and 17 live deliveries were achieved. The abortion rate and take home baby rate were better than the TESE-ICSI in nonobstructive azoospermic patients. In their offspring we could not find any abnormalities and mental retardation. CONCLUSIONS Testicular sperm could be retrieved in 48.4% of persistent azoospermic men after chemotherapy, and could be used to achieve delivery of healthy children. TESE-ICSI in the azoospermic cancer survivor is a safe treatment option when no spermatozoa were frozen before chemotherapy. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e913-e914 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiroshi Okada Koshigaya, Japan More articles by this author Yoshitomo Kobori Koshigaya, Japan More articles by this author Hiroaki Aoki Koshigaya, Japan More articles by this author Ryo Sato Koshigaya, Japan More articles by this author Yoshio Ashizawa Koshigaya, Japan More articles by this author Hiroshi Yagi Koshigaya, Japan More articles by this author Gaku Arai Koshigaya, Japan More articles by this author Shigehiro Soh Koshigaya, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...